CN116173076A - Liver-protecting and alcohol-dispelling composition and application thereof - Google Patents
Liver-protecting and alcohol-dispelling composition and application thereof Download PDFInfo
- Publication number
- CN116173076A CN116173076A CN202211469341.4A CN202211469341A CN116173076A CN 116173076 A CN116173076 A CN 116173076A CN 202211469341 A CN202211469341 A CN 202211469341A CN 116173076 A CN116173076 A CN 116173076A
- Authority
- CN
- China
- Prior art keywords
- cfu
- multiplied
- equal
- liver
- bacteria contained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 210000004185 liver Anatomy 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 25
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 24
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 24
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 24
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 24
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 23
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract description 16
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 15
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 15
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 15
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 9
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims description 53
- 239000000843 powder Substances 0.000 claims description 28
- 235000009508 confectionery Nutrition 0.000 claims description 22
- 206010019133 Hangover Diseases 0.000 claims description 18
- 239000000796 flavoring agent Substances 0.000 claims description 16
- 229920001542 oligosaccharide Polymers 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 11
- 150000002482 oligosaccharides Chemical class 0.000 claims description 10
- 240000006063 Averrhoa carambola Species 0.000 claims description 9
- 235000010082 Averrhoa carambola Nutrition 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 7
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 7
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960000511 lactulose Drugs 0.000 claims description 6
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- -1 lactulose oligosaccharides Chemical class 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229940068517 fruit extracts Drugs 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 230000035622 drinking Effects 0.000 abstract description 39
- 230000000968 intestinal effect Effects 0.000 abstract description 19
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 7
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- 206010015137 Eructation Diseases 0.000 abstract description 4
- 206010019233 Headaches Diseases 0.000 abstract description 4
- 206010028813 Nausea Diseases 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 4
- 231100000869 headache Toxicity 0.000 abstract description 4
- 206010022437 insomnia Diseases 0.000 abstract description 4
- 230000008693 nausea Effects 0.000 abstract description 4
- 208000036649 Dysbacteriosis Diseases 0.000 abstract description 3
- 208000027244 Dysbiosis Diseases 0.000 abstract description 3
- 206010067125 Liver injury Diseases 0.000 abstract description 3
- 230000007140 dysbiosis Effects 0.000 abstract description 3
- 231100000753 hepatic injury Toxicity 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 description 23
- 230000006838 adverse reaction Effects 0.000 description 23
- 239000003826 tablet Substances 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 235000014101 wine Nutrition 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000004977 Hueckel calculation Methods 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 230000035987 intoxication Effects 0.000 description 5
- 231100000566 intoxication Toxicity 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000002075 anti-alcohol Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000702462 Akkermansia muciniphila Species 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 description 2
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- AANMVENRNJYEMK-UHFFFAOYSA-N 4-propan-2-ylcyclohex-2-en-1-one Chemical compound CC(C)C1CCC(=O)C=C1 AANMVENRNJYEMK-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 240000000716 Durio zibethinus Species 0.000 description 1
- 235000006025 Durio zibethinus Nutrition 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 244000010000 Hovenia dulcis Species 0.000 description 1
- 235000008584 Hovenia dulcis Nutrition 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000012488 Opiate Overdose Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000095588 Ruminococcaceae Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009447 edible packaging Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 239000009270 zilongjin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a composition for protecting liver and dispelling effects of alcohol and application thereof, wherein the composition comprises bifidobacterium adolescentis, lactobacillus plantarum, lactobacillus rhamnosus, stachyose and 2' -fucosyllactose. The composition can greatly relieve intestinal dysbacteriosis and liver injury after drinking, thereby improving symptoms such as gastrointestinal discomfort, diarrhea, nausea, eructation, headache, insomnia and the like.
Description
Technical Field
The invention belongs to the technical field of health products, and particularly relates to a composition for protecting liver and dispelling effects of alcohol and application thereof.
Background
With the rise of economic level and the development of domestic wine industry, the number of alcoholism or alcohol abuse is increased year by year, and the number of alcoholic liver diseases including fatty liver, alcoholic hepatitis, liver fibrosis and liver cirrhosis, and even liver cancer possibly after deterioration.
Alcohol can cause damage to a number of end organs, mainly the liver, gut and brain. It is a relevant objective to study the intestinal microbial environment during the development of alcohol-induced damage.
One term describing changes in the composition of intestinal microorganisms is "microbiota," roughly defined as an imbalance or change in microbiota, which can adversely affect the host. Alterations in intestinal flora are described in various diseases such as cirrhosis, inflammatory Bowel Disease (IBD), parkinson's disease, autism and clostridium difficile infection.
The intestinal-hepatic axis is the main pathway for the development and progression of alcoholic liver disease. This gut-liver axis is associated with gut immune response, gut barrier function, liver and systemic inflammation and can be severely destroyed during alcoholic liver disease.
The intestinal barrier is an important component of the intestinal-hepatic axis, and in rodent studies, specific decreases in intestinal microbial activity and expression by intestinal hypoxia inducible factor 1 alpha affect alcohol-related changes in intestinal permeability that can be treated by the probiotic lactobacillus rhamnosus (LGG) and reversed by modulating saturated and unsaturated fat intake. Hypoxia-inducible factor 1 alpha is also important in the occurrence of alcohol-related liver steatosis. Alcohol is also associated with a relative increase in the abundance of enterobacteria that produce endotoxin and a decrease in the population that produces Short Chain Fatty Acids (SCFAs), such as the chaetoceridae and ruminococcaceae.
There is growing evidence that modulation of intestinal microorganisms can have beneficial effects on the treatment of alcoholic diseases and on recovery after drinking. Studies have shown that administration of akkermansia muciniphila (a. Muciniphila) and LGG improved alcohol-induced injury through complex intestinal barrier changes and systemic inflammation in a mouse model. Additional studies have shown that probiotic administration for 5 days (bifidobacterium bifidum and lactobacillus plantarum 8P-A3) can increase the levels of potentially beneficial bacteria such as bifidobacterium and lactobacillus in patients hospitalized with alcohol. At the same time, liver-related enzyme (alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transpeptidase) levels were also improved in patients with mild alcoholic hepatitis.
Breast milk oligosaccharides (HMOs) are a class of oligosaccharides composed of monosaccharide molecules that naturally occur in human milk, having a certain sweetness but being relatively low, about only 30-50% of sucrose. The content of the solid components in human milk is high, next to lactose and fat, in particular in colostrum 22-23g/L, but the concentration will steadily decrease during the period of several months after birth of the infant, and the content in mature milk will decrease to about 12-13g/L. Of these, 2' -fucosyllactose is the most abundant of all HMOs.
HMOs have several biological functions, most importantly, can maintain the microecological balance of the gut. Because HMOs are not destroyed by gastric acid of human body and decomposed by digestive enzymes, they can directly reach large intestine, stimulate growth of beneficial flora (bifidobacterium and lactobacillus) in intestinal tract, indirectly inhibit growth of harmful flora, and maintain intestinal microecological balance, therefore, HMOs are regarded as 1 st prebiotics (prebiotics) of human body. The number of bifidobacteria in the gut of breast-fed infants is significantly greater than that of infants fed with formula, as HMOs are able to stimulate the growth of part of the bifidobacteria. Other biological functions of HMOs are also to fight pathogenic bacterial infection, regulate immunity, inhibit inflammatory responses, promote brain development, etc.
The existing medicines for treating alcoholism or quick sobering up comprise metadoxine, naloxone, acamprosate, topiramate and the like, and the medicines have some anti-hangover effects, but have a plurality of adverse reactions. For example, metadoxine is an acetaldehyde dehydrogenase activator, and can antagonize the decline of alcohol dehydrogenase activity caused by acute and chronic alcoholism and accelerate the excretion of alcohol and metabolites thereof, acetaldehyde and ketone bodies, through urine. In healthy volunteers, metadoxine can reduce the half-life of ethanol metabolism from 7 hours 15 minutes to 5 hours 50 minutes. It should be noted in particular that metadoxine may cause peripheral nerve diseases. Naloxone is an antidote for opioid overdose, and also can relieve central inhibition of alcohol and shorten coma time, but may cause manic side effects.
Most of the components of the domestic anti-alcohol products are kudzuvine root, hovenia dulcis thunb, turmeric, roxburgh rose powder, inulin and the like, and the products have certain anti-alcohol function. The substances are mostly substances commonly used in traditional Chinese medicine, and the components are relatively complex, and the effects brought by certain components in the substances can be possibly relied on, for example, bioactive substances such as pueraria isoflavone and the like contained in the pueraria are used for removing ethanol and metabolites thereof by improving the activities of liver ethanol dehydrogenase and acetaldehyde dehydrogenase. The active ingredients such as peroxidases contained in semen Hoveniae have effects of relieving hangover and tranquilizing.
The prior art also has the benefit that the prebiotic and probiotic composition or solid beverage can regulate intestinal tracts and protect livers. But the types and the amounts of the probiotics strains used are different. Up to now, there is no formulation and study for the combined use of 2' -fucosyllactose and prebiotics, probiotics for alleviating drunkenness, protecting the liver, recovering after drinking.
Disclosure of Invention
The invention aims to solve the technical problems of overcoming the defects in the prior art, and provides a composition for protecting liver and dispelling effects of alcohol and application thereof, which can greatly relieve intestinal dysbacteriosis and liver injury after drinking, thereby improving symptoms such as gastrointestinal discomfort, diarrhea, nausea, eructation, headache, insomnia and the like.
In order to solve the technical problems, the invention adopts the following technical scheme:
a composition for protecting liver and alleviating hangover comprises Bifidobacterium adolescentis, lactobacillus plantarum, lactobacillus rhamnosus, stachyose and 2' -fucosyllactose.
Preferably, fructooligosaccharides are also included;
preferably, the method further comprises xylo-oligosaccharide.
Preferably, lactulose oligomer is also included;
preferably, the composition further comprises galactooligosaccharides;
preferably, soy oligosaccharides are also included.
Preferably, a flavoring agent is also included;
preferably, the flavour is selected from fruit extracts, vegetable protein flavours or flavours;
preferably, the fruit extract is selected from the group consisting of carambola extract.
Preferably, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
Preferably, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
Preferably, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
Preferably, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
In order to solve the technical problems, the invention adopts the following technical scheme:
use of a composition for protecting liver and alleviating hangover as described above for the preparation of a product having liver-protecting and alleviating hangover effects, the product being a food composition or a pharmaceutical composition.
Preferably, the pharmaceutical composition is in the form of an oral dosage form, the oral dosage form being a powder, granule, tablet, solution or capsule, and the food composition being a solid beverage, liquid beverage, tabletted candy or soft candy.
The invention provides application of 2' -fucosyllactose in preparing medicines or foods for protecting liver and dispelling effects of alcohol.
Due to the adoption of the technical scheme, compared with the prior art, the invention has the following advantages:
1. the composition of the invention promotes gastrointestinal motility, inhibits overgrowth of small intestine bacteria and promotes discharge of gastrointestinal discomfort;
2. the invention forms beneficial bacteria and oligosaccharide protection in the gastrointestinal tract, and avoids bacterial translocation;
3. the invention regulates intestinal flora, promotes the growth of beneficial flora and inhibits harmful proliferation;
4. the invention can greatly relieve intestinal dysbacteriosis and liver injury after drinking, thereby improving symptoms such as gastrointestinal discomfort, diarrhea, nausea, eructation, headache, insomnia and the like.
Detailed Description
In order to make the technical scheme and the beneficial effects of the invention more obvious and understandable, the following detailed description is given by way of example. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention.
The specific techniques or conditions not identified in the examples are generally performed according to conventional techniques or conditions described in the literature in this field or according to the specifications of the product and the conditions suggested by the manufacturer.
Unless otherwise indicated, the various starting materials and reagents are either commercially available or synthesized according to known methods, and are used without further purification, and unless otherwise indicated, commercially available manufacturers include, but are not limited to, shandong's California Biotechnology Co., ltd, shandong Bailong Crypton Biotechnology Co., ltd, guangzhou Baolai Biotechnology Co., lanzhou Volterray Biotechnology Co., ltd, and Suzhou one part Biotechnology Co., etc. The preparation of 2' -fucosyllactose in the examples is described in the patent application publication No. CN 112029790A.
The structure of the 2' -fucosyllactose is
CAS RN is 41263-94-9.
The invention relates to a composition for protecting liver and dispelling effects of alcohol, which comprises bifidobacterium adolescentis, lactobacillus plantarum, lactobacillus rhamnosus, stachyose and 2' -fucosyllactose.
In the composition of the invention, the 2' -fucosyllactose can promote healthy intestinal flora.
In the composition, bifidobacterium adolescentis, lactobacillus plantarum and lactobacillus rhamnosus are live bacteria preparations, have the effects of balancing intestinal flora, inhibiting potential pathogenic bacteria and increasing intestinal mucosa resistance, and meanwhile, utilize probiotics to improve the intestinal flora structure.
In the composition, stachyose has the effect of relaxing bowel, has obvious proliferation effect on beneficial bacteria such as bifidobacteria, lactobacillus and the like in human gastrointestinal tracts, can rapidly improve the environment in human gastrointestinal tracts, and can regulate the balance of micro-ecological bacteria.
In certain embodiments, the composition further comprises fructo-oligosaccharides, xylo-oligosaccharides, lacto-oligosaccharides, galacto-oligosaccharides or soy oligosaccharides, which form a protective film on the gastric mucosal surface as much as possible in the stomach, avoiding direct irritation of the gastric wall by alcohol while also reducing the rate of alcohol absorption by the stomach; but also can promote the intestinal colonization of probiotics, the intestinal convergence and the reduction of the pH environment of the intestinal canal, is not utilized by most of intestinal putrefying bacteria, but can promote the growth and propagation of beneficial bacteria lactobacillus and bifidobacterium in human bodies, thereby inhibiting the growth of putrefying bacteria and being beneficial to improving and maintaining the normal functions of the intestinal canal.
In certain embodiments, the composition further comprises a flavoring agent for enhancing the flavor of the combination.
In certain embodiments, the flavoring agent is selected from a fruit extract, a vegetable protein flavoring agent, or an edible essence.
In certain embodiments, the fruit extract is one of a crisp pear, a navel orange, a banana, a blueberry, a watermelon, an apple, a strawberry, a pineapple, a mango, a juicy peach, or a durian.
In certain embodiments, the vegetable protein flavor is one of a vegetable protein chicken flavor, a vegetable protein fresh shrimp flavor, or a vegetable protein beef flavor.
In a specific embodiment, the fruit extract is selected from carambola extract, wherein the carambola has rich saccharide, vitamin C and organic acid, can rapidly supplement water to quench thirst, and can expel heat or alcohol from the body along with urine; meanwhile, the carambola can protect the liver and reduce blood sugar.
In a specific embodiment, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
In a specific embodiment, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
In a specific embodiment, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
In a specific embodiment, the composition comprises the following components in parts by weight:
wherein the number of active bacteria contained in Bifidobacterium adolescentis is not less than 1×10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
In certain embodiments, stachyose may be 0.4-1.0 parts, preferably 0.6-0.8 parts, more specifically may be 0.4, 0.5, 0.6, 0.8, 1.0, 1.2 parts by weight.
In certain embodiments, the 2' -fucosyllactose may be in the range of 0.03-0.08, preferably 0.04-0.07, more specifically may be 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 1.0 parts by weight.
In certain embodiments, the fructooligosaccharides may be present in an amount of 0.6 to 1.2 parts, preferably 0.8 to 1.0 parts, and more specifically may be present in an amount of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.5 parts by weight.
In certain embodiments, the xylo-oligosaccharide may be 0.6 to 1.2 parts, preferably 0.8 to 1.0 parts, more specifically 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.5 parts by weight.
In certain embodiments, the lactulose oligomer may be more specifically 0.2, 0.3, 0.4, 0.5, 0.6 parts by weight.
In certain embodiments, the galacto-oligosaccharides may more particularly be 0.2, 0.3, 0.4, 0.5, 0.6 parts by weight.
In certain embodiments, the soy oligosaccharide may more particularly be 0.1, 0.2, 0.3 parts by weight.
In certain embodiments, the carambola extract can more specifically be 0.1, 0.2, 0.3 parts by weight.
In certain embodiments, the use of a composition for protecting liver and alleviating hangover as described above for the preparation of a product having liver-protecting and alleviating hangover effects.
In certain embodiments, the product having liver protecting and anti-hangover effects is a food composition or a pharmaceutical composition.
In certain embodiments, the pharmaceutical composition is an oral dosage form, the oral dosage form being a powder, granule, tablet, solution or capsule, and the food composition is a solid beverage, liquid beverage, tabletted candy or soft candy.
The invention provides application of 2' -fucosyllactose in preparing medicines or foods for protecting liver and dispelling effects of alcohol.
Comparative example
The composition for protecting liver and dispelling effects of alcohol comprises the following components:
| name of the name | Weight (g) |
| Bifidobacterium adolescentis | 0.4 |
| Lactobacillus plantarum | 0.1 |
| Lactobacillus rhamnosus | 0.1 |
| Fructooligosaccharides | 0.5 |
| Xylooligosaccharide | 0.5 |
| Stachyose | 0.4 |
| Lactulose oligosaccharides | 0.2 |
| Galacto-oligosaccharides | 0.2 |
| Soybean oligosaccharide | 0.1 |
| Carambola extract | 0.1 |
In the table, the specification of the bifidobacterium adolescentis is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU，
The specification of the lactobacillus plantarum is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU，
The specification of lactobacillus rhamnosus is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU。
Weighing all raw materials according to the dosage in the table, and putting into a homogenizing machine for uniform mixing. And then pouring the mixture into a hopper of a tablet press, and adjusting machine parameters to obtain the liver-protecting and anti-alcohol tablet candy containing probiotics, wherein the quality requirements of the tablet candy are met.
Example 1
The composition for protecting liver and dispelling effects of alcohol comprises the following components:
| name of the name | Weight (g) |
| Bifidobacterium adolescentis | 0.4 |
| Lactobacillus plantarum | 0.1 |
| Lactobacillus rhamnosus | 0.1 |
| Fructooligosaccharides | 0.5 |
| Xylooligosaccharide | 0.5 |
| Stachyose | 0.4 |
| Lactulose oligosaccharides | 0.2 |
| Galacto-oligosaccharides | 0.2 |
| Soybean oligosaccharide | 0.1 |
| Carambola extract | 0.1 |
| 2' -fucosyllactose | 0.03 |
In the table, the specification of the bifidobacterium adolescentis is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU，
The specification of the lactobacillus plantarum is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU，
The specification of lactobacillus rhamnosus is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU。
Weighing all raw materials according to the dosage in the table, and putting into a homogenizing machine for uniform mixing. And then pouring the mixture into a hopper of a tablet press, and adjusting machine parameters to obtain the liver-protecting and anti-alcohol tablet candy containing probiotics, wherein the quality requirements of the tablet candy are met.
Effect testing
Subjects were recruited and subject conditions were as follows:
1. the male and female are unlimited, and the ages are 18-70 years old;
2. body mass index: BMI of 18.5.ltoreq.BMI<30.0 kg/square meter (calculation method: weight kg/(height m)) 2 )；
3. The defecation times are normal for the last six months every week;
4. normal life work, diet and exercise habit can be maintained during the participation test;
5. no organic intestinal diseases;
6. no history of significant gastrointestinal disease;
7. no history of abdominal surgery;
8. no history of diabetes;
9. self-assessment daily affordable drinking amounts were between 100ml and 200 ml.
Subjects were enrolled for 50 subjects under the conditions described above for testing.
The subjects were randomly divided into five groups of 10 ABCDE and tested according to the following procedure.
Group A:
first drinking: without any measures, 150ml of wine is drunk in dinner of the first day, and the people work and live normally the next day. Record the condition after drinking and adverse reaction.
Second drinking (after 1 week): the subject takes a piece of common tabletting candy orally 60 minutes before drinking, does not contain the composition components, drinks 150ml at dinner, and works and lives normally the next day. Record the condition after drinking and adverse reaction.
Group B:
first drinking: without any measures, 150ml of wine is drunk in dinner of the first day, and the people work and live normally the next day. Record the condition after drinking and adverse reaction.
Second drinking (after 1 week): the subjects orally took one comparative example tablet candy 60 minutes before drinking, 150ml of wine was drunk at dinner, and one comparative example tablet candy was taken again after getting up in the morning the next day, and the subjects normally work and live, and the condition and adverse reaction after drinking were recorded.
Group C:
first drinking: without any measures, 150ml of wine is drunk in dinner of the first day, and the people work and live normally the next day. Record the condition after drinking and adverse reaction.
Second drinking (after 1 week): the subject took the tablet candy of example 1 60 minutes before drinking, 150ml of wine was drunk at dinner, and the following day was normal work and life. Record the condition after drinking and adverse reaction.
Group D:
first drinking: without any measures, 150ml of wine is drunk in dinner of the first day, and the people work and live normally the next day. Record the condition after drinking and adverse reaction.
Second drinking (after 1 week): the subjects drink 150ml of wine at dinner, take one tablet candy of example 1 orally after getting up in the morning the next day, work and live normally, record the condition after drinking and adverse reaction.
Group E:
first drinking: without any measures, 150ml of wine is drunk in dinner of the first day, and the people work and live normally the next day. Record the condition after drinking and adverse reaction.
Second drinking (after 1 week): the subject took one example 1 tabletted candy 60 minutes before drinking, 150ml of drinking at dinner, and one example 1 tabletted candy again after getting up the next morning, and was working and living normally, and the post-drinking condition and adverse reaction were recorded.
Adverse reaction refers to gastrointestinal discomfort, diarrhea, constipation, nausea, belching, headache, insomnia, etc.
The test results are shown in table 1:
table 1 adverse reaction reporting results for each group
Table 1 illustrates:
(1) group a (1) represents the results reported after the first drinking of group a, and group a (2) represents the results reported after the second drinking of group a, otherwise this rule is also referred to.
(2) If 4 persons report gastrointestinal discomfort after the first drinking of the group A, namely the report frequency of the gastrointestinal discomfort corresponding to the group A (1) is recorded as 4, the rule is also referred to.
(3) Since each person may have a plurality of different adverse reactions, the calculation formula of the occurrence rate of the adverse reactions is as follows:
wherein denominator (total number of all adverse reactions per group) refers to the product of 10 persons per group times the 7 adverse reactions each person in table 1 may have. For example, group a 10 persons multiply by 7, i.e., the denominator is 70.
From the results of table 1 above, the following conclusions can be drawn:
1. adverse reactions to a certain extent can be brought after drinking wine, and the adverse reactions can be different from person to person;
2. the oral administration of the tabletted candy of example 1 before drinking can control the incidence of adverse reactions to a certain extent;
3. the tablet candy of the example 1 can control the incidence of adverse reaction to a certain extent after drinking, and the effect is worse than that before drinking;
4. the tabletted candy of example 1 can effectively control the occurrence rate of adverse reaction before and after drinking, and has the best effect.
5. The tablet candy of the comparative example can control the occurrence rate of adverse reaction to a certain extent before and after drinking, but the tablet candy of the example 1 has much poorer effect.
Example 2
The composition for protecting liver and dispelling effects of alcohol comprises the following components:
| name of the name | Weight (g) |
| Bifidobacterium adolescentis | 0.6 |
| Lactobacillus plantarum | 0.4 |
| Lactobacillus rhamnosus | 0.3 |
| Fructooligosaccharides | 1.5 |
| Xylooligosaccharide | 1.5 |
| Stachyose | 1.2 |
| Lactulose oligosaccharides | 0.6 |
| Galacto-oligosaccharides | 0.6 |
| Soybean oligosaccharide | 0.3 |
| Carambola extract | 0.3 |
| 2' -fucosyllactose | 0.1 |
In the table, the specification of the bifidobacterium adolescentis is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU，
The specification of the lactobacillus plantarum is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU，
The specification of lactobacillus rhamnosus is that the number of active bacteria contained in each gram is more than or equal to 1 multiplied by 10 10 CFU。
Weighing each raw material according to the dosage in the table, drying at 60 ℃ for several hours, and sieving. And then placing the mixture into a homogenizing machine for uniformly mixing, and packaging into an edible packaging bag for packaging.
Effect testing
Taking one part of the solid beverage, dissolving the solid beverage into 50ml of purified water, and uniformly stirring.
SPF-grade ICR female mice (20+ -5 g) were taken and randomly divided into 3 groups of 5 animals each, and the experiment was started after 1 week of adaptive feeding.
Group a (blank rental): 0.1ml/10g purified water is administered once through oral gastric lavage, and the condition of the mice is observed;
group B (negative control group): 0.1ml/10g of purified water is administered once through oral gavage, after waiting for 60 minutes, 0.3ml/10g (intoxication amount) of 52-degree white wine is administered through oral gavage, the condition of a mouse is observed, and the time from intoxication to sobering is recorded;
group C (experimental group): after a solid beverage (containing the above composition) of 0.1ml/10g was administered once by oral gavage and 60 minutes, a white spirit of 52 degrees of 0.3ml/10g (intoxication amount) was administered by oral gavage, and the condition of the mice was observed and the time from intoxication to sobering was recorded.
The intoxication time is defined as the onset of loss of the eversion and the sober-up time is defined as the recovery of the eversion.
After 24 hours, animals were sacrificed, blood samples were taken, and the content of glutamic pyruvic transaminase (ALT) and glutamic oxaloacetic transaminase (AST) in serum was measured.
TABLE 2 results of mice drunk recovery experiments
The experimental result shows that the drunk time of the negative control group is smaller than that of the experimental group, and the sobering-up time is far longer than that of the experimental group. In addition, on serology level, ALT and AST values of a negative control group are obviously increased, and the difference is remarkable, so that the beverage provided by the invention has the effects of protecting liver and dispelling effects of alcohol.
It should be understood that the above examples are illustrative and are not intended to encompass all possible implementations encompassed by the claims. Various modifications and changes may be made in the above embodiments without departing from the scope of the disclosure. Likewise, the individual features of the above embodiments can also be combined arbitrarily to form further embodiments of the invention which may not be explicitly described. Therefore, the above examples merely represent several embodiments of the present invention and do not limit the scope of protection of the patent of the present invention.
Claims (10)
1. A composition for protecting liver and alleviating hangover, which is characterized by comprising the following components in percentage by weight: including bifidobacterium adolescentis, lactobacillus plantarum, lactobacillus rhamnosus, stachyose and 2' -fucosyllactose.
2. The liver protecting and anti-hangover composition according to claim 1, wherein: also included are fructooligosaccharides;
preferably, the method further comprises xylo-oligosaccharide.
3. The liver protecting and anti-hangover composition according to claim 1, wherein: also included are lactulose oligosaccharides;
preferably, the composition further comprises galactooligosaccharides;
preferably, soy oligosaccharides are also included.
4. The liver protecting and anti-hangover composition according to claim 1, wherein: also comprises flavoring agent;
preferably, the flavour is selected from fruit extracts, vegetable protein flavours or flavours;
preferably, the fruit extract is selected from carambola extract.
5. The liver protecting and anti-hangover composition according to claim 1, wherein: the coating comprises the following components in parts by weight:
wherein the number of active bacteria contained in the bifidobacterium adolescentis is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in the lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
6. The liver protecting and anti-hangover composition according to claim 1, wherein: the coating comprises the following components in parts by weight:
wherein the number of active bacteria contained in the bifidobacterium adolescentis is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in the lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
7. The liver protecting and anti-hangover composition according to claim 1, wherein: the coating comprises the following components in parts by weight:
wherein the number of active bacteria contained in the bifidobacterium adolescentis is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in the lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
8. The liver protecting and anti-hangover composition according to any one of claims 1-7, characterized in that: the coating comprises the following components in parts by weight:
wherein the number of active bacteria contained in the bifidobacterium adolescentis is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in the lactobacillus plantarum is more than or equal to 1 multiplied by 10 10 The CFU is used in the form of a powder,
the number of active bacteria contained in lactobacillus rhamnosus is more than or equal to 1 multiplied by 10 10 CFU/serving.
9. Use of a composition for protecting liver and alleviating hangover according to any one of claims 1-8, in the preparation of a product with liver-protecting and alleviating hangover effect, said product being a food composition or a pharmaceutical composition;
preferably, the pharmaceutical composition is an oral dosage form, the oral dosage form is a powder, a granule, a tablet, a solution or a capsule, and the food composition is a solid beverage, a liquid beverage, a tabletted candy or a soft candy.
Use of 2' -fucosyllactose in the preparation of a medicament or food for protecting liver against alcohol effects.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211469341.4A CN116173076A (en) | 2022-11-22 | 2022-11-22 | Liver-protecting and alcohol-dispelling composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211469341.4A CN116173076A (en) | 2022-11-22 | 2022-11-22 | Liver-protecting and alcohol-dispelling composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116173076A true CN116173076A (en) | 2023-05-30 |
Family
ID=86437124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211469341.4A Pending CN116173076A (en) | 2022-11-22 | 2022-11-22 | Liver-protecting and alcohol-dispelling composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116173076A (en) |
-
2022
- 2022-11-22 CN CN202211469341.4A patent/CN116173076A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4793533B2 (en) | Stimulation of the immune system with polydextrose | |
| RU2475051C2 (en) | Infant food containing unviable bifidobacteria and indigestible oligosaccharides | |
| RU2607457C2 (en) | Milk oligosaccharide-galactooligosaccharide composition for infant formula, containing soluble oligosaccharide fraction present in milk, and having low level of monosaccharides, and process to produce composition | |
| RU2358474C2 (en) | Prebiotic compositions | |
| RU2581731C2 (en) | Mixture of oligosaccharides and food product containing said mixture, in particular nutritional mixture for infant feeding | |
| CN113662199A (en) | Human milk oligosaccharides for preventing gastrointestinal damage and/or promoting gastrointestinal healing | |
| EP3335576A1 (en) | Human milk oligosaccharides to promote growth of beneficial bacteria | |
| RU2735250C2 (en) | COMPOSITION CONTAINING 2FL AND LNnT TO CONTROL FOOD CONSUMPTION AND GROWTH IN INFANTS OR YOUNG CHILDREN | |
| JP7280069B2 (en) | A composition for preventing or improving functional gastrointestinal disorders, and pharmaceutical compositions and food and drink compositions using the composition for preventing or improving functional gastrointestinal disorders | |
| CN111683665A (en) | Human milk oligosaccharides for microbiota regulation and synthetic compositions thereof | |
| WO2004000340A2 (en) | Method and composition for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract | |
| AU2022203298A1 (en) | Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rota virus-associated diarrhoea | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| AU2019241546A2 (en) | Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition | |
| AU2021213420A2 (en) | Formula with galactomannan gum and non digestible oligosaccharides | |
| US9826766B2 (en) | Use of polysaccharides for the intestinal well-being of nursing infants and/or infants | |
| US20190070204A1 (en) | Proliferative agent for faecalibacterium | |
| CN112167639A (en) | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof | |
| US11969447B2 (en) | Use of spray-dried powder derived from lactic acid bacterial strains and herbal extracts for promoting defecation | |
| WO2022266058A1 (en) | Methods and compositions for treating gas | |
| CN116173076A (en) | Liver-protecting and alcohol-dispelling composition and application thereof | |
| WO2014134830A1 (en) | Edible composition, food product comprising same, and preparation method for the food product | |
| CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| CN110801474A (en) | Composition for preventing and treating constipation and application thereof | |
| EP2604123A1 (en) | Method and nutritional compositions for the treatment of diarrhea. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |